Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Apr 29, 2024--
(Bloomberg) -- David Einhorn’s Greenlight Capital underperformed the “fundamentally broken” stock market at the start of the year, according to a letter to investors.Most Read from BloombergBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsTaylor Swift Is Proof That How We Critique Music Is BrokenZuckerberg Asks for Patience After Meta’s AI Push Irks InvestorsTech Giants Hit in Late Hours After Meta’s Outlook: Markets WrapFlorida’s Home Insurance Industry May Be Worse Than
“This historic shifting of capital is a beautiful opportunity set in which we can invest.”
In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023.
Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.53% from the company’s previous close. Other research analysts […]